INNOVIVA, INC. Accounts Receivable, Allowance for Credit Loss
INNOVIVA, INC. (INVA) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2018-02-23
- 2017-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2016-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2015-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2014-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-23 |
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2016-02-24 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-07 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |